SpringWorks Therapeutics Files Definitive Proxy Statement

Springworks Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanySpringworks Therapeutics, Inc.
Form TypeDEF 14A
Filed DateApr 4, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: SWTX

TL;DR

SWTX proxy statement out - vote on directors & auditors for 2025.

AI Summary

SpringWorks Therapeutics, Inc. filed its definitive proxy statement on April 4, 2025, for its annual meeting of stockholders. The filing outlines the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm for the fiscal year ending December 31, 2025. The company is seeking shareholder approval for these matters.

Why It Matters

This filing is crucial for shareholders as it details the agenda for the annual meeting, including director elections and auditor ratification, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine annual filing and does not contain new material financial or strategic information that would inherently increase risk.

Key Players & Entities

  • SpringWorks Therapeutics, Inc. (company) — Registrant
  • 0001104659-25-032187.txt (document) — Filing document name
  • 20250404 (date) — Filing date
  • 20250514 (date) — Conformed period of report
  • 001-39044 (identifier) — SEC file number

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with the definitive proxy statement for SpringWorks Therapeutics, Inc.'s annual meeting of stockholders, outlining proposals for voting.

When was this proxy statement filed?

This proxy statement was filed on April 4, 2025.

What is the reporting period for this filing?

The conformed period of report is May 14, 2025.

What are the main items shareholders will vote on?

Shareholders will vote on proposals including the election of directors and the ratification of the appointment of the independent registered public accounting firm.

What is the company's fiscal year end?

The company's fiscal year end is December 31.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 4, 2025 regarding SpringWorks Therapeutics, Inc..

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.